论文部分内容阅读
为探讨组织型纤溶酶原激活物(t—PA)在乳癌组织内的水平状况,我们用底物发色法测定69例乳癌组织和33例乳房纤维瘤组织t—PA值,并结合患者临床分明。淋巴结转移情况、月经状况、雌孕激素受体、多药耐药基因表达状况进行分析.结果表明:t—PA值在乳癌组(n=69)为98±47Iu/mg蛋白,略高于纤维瘤组(87±40,n=33,无统计学差别,激素受体(ER,PR)双阳性组t—PA值(125±37)显著高于其他组,随临床分期Ⅰ→Ⅲ,t—PA值呈显著下降趋势(P<0.01),t—PA值与其他临床病理参数无相关性。t—PA值可以补充说明体内雌孕激素受体功能状态,为激素疗法提供更多信息并提示临床病程。
To investigate the level of tissue-type plasminogen activator (t-PA) in breast cancer tissues, we used substrate chromogenic assay to measure t-PA values in 69 cases of breast cancer and 33 cases of breast fibroids in combination with patients. Clinically clear. Lymph node metastasis, menstruation, estrogen and progesterone receptors, and multidrug resistance gene expression were analyzed. The results showed that the t-PA value in the breast cancer group (n=69) was 98±47Iu/mg protein, slightly higher than fiber In the tumor group (87±40, n=33, no statistical difference, the hormone receptor (ER, PR) double positive group t-PA value (125±37) was significantly higher than other groups, with the clinical stage I → III, t The PA value showed a significant downward trend (P<0.01), and t-PA value had no correlation with other clinicopathological parameters.The t-PA value could supplement the estrogen and progesterone receptor function status in vivo and provide more information for hormone therapy. Prompt clinical course.